Medicare dropped a confidentiality requirement that banned pharmaceutical companies from publicly discussing drug price negotiations set to begin this fall.
Drugmakers had sued the federal government, arguing that the requirement violated the First Amendment. In initial guidance released in March, Medicare had forbidden the industry from publicly disclosing information on the lower price initially offered by the federal government for drugs targeted under the program, as well as the government's reasons for selecting that price point.
این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب: